Pegvisomant Pfizer/Sensus.
Copyright policy )Pegvisomant Pfizer/Sensus.
Pfizer (formerly Pharmacia), in collaboration with its wholly owned subsidiary Sensus, has developed and launched pegvisomant, a pegylated, genetically modified human growth hormone (hGH), for the treatment of acromegaly. Pegvisomant, in contrast to classical somatostatin analogs which lower hGH synthesis, exerts its anti-hGH action by preventing GH receptor activation. This drug is now available in the US and Europe for the treatment of acromegaly.
Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Human Growth Hormone, Delayed-Action Preparations, Injections, Subcutaneous, Acromegaly, Animals, Humans, Receptors, Somatotropin
Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Human Growth Hormone, Delayed-Action Preparations, Injections, Subcutaneous, Acromegaly, Animals, Humans, Receptors, Somatotropin
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).4 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!